Table 1 Clinicopathologic characteristics of DCIS in comparison with DCISMI in the study cohort
Features | DCIS (n = 42) | DCISMI (n = 45) | P value |
|---|---|---|---|
MRI protocols | 0.36 | ||
 GE | 28(66.7%) | 34(75.6%) | |
 SIEMENS | 14(33.3%) | 11(24.4%) | |
Age, years | 42.76 ± 8.742 | 45.71 ± 9.577 | 0.1382 |
BMI | 23.25 ± 3.405 | 22.10 ± 2.548 | 0.0772 |
ER status | 0.0191 | ||
 Negative | 12(28.57%) | 24(53.33%) | |
 Positive | 30(71.43%) | 21(46.67%) | |
PR status | 0.0074 | ||
 Negative | 15(35.71%) | 29(64.44%) | |
 Positive | 27(64.29%) | 16(35.56%) | |
HER2 status | 0.0878 | ||
 Negative | 15(35.71%) | 8(17.78%) | |
 Positive | 27(64.29%) | 37(82.22%) | |
Ki-67 proliferation index (%) | 0.519 | ||
  < 20 | 25(59.52%) | 23(51.11%) | |
 ≧20 | 17(40.48%) | 22(48.89%) | |
p63 | 0.0004 | ||
 Negative | 2(4.76%) | 16(35.56%) | |
 Positive | 40(95.24%) | 29(64.44%) | |
Nuclear grade | 0.0006 | ||
 Low | 9(21.43%) | 2(4.44%) | |
 Intermediate | 16(38.1%) | 7(15.56%) | |
 High | 17(40.47%) | 36(80%) | |
Axillary lymph node metastasis | 0.4948 | ||
 Negative | 42(100%) | 43(95.56%) | |
 Positive | 0 | 2(4.44%) |